TY - JOUR
T1 - T cells redirected to a minor histocompatibility antigen instruct intratumoral TNFα expression and empower adoptive cell therapy for solid tumors
AU - Manzo, Teresa
AU - Sturmheit, Tabea
AU - Basso, Veronica
AU - Petrozziello, Elisabetta
AU - Michelini, Rodrigo Hess
AU - Riba, Michela
AU - Freschi, Massimo
AU - Elia, Angela R.
AU - Grioni, Matteo
AU - Curnis, Flavio
AU - Protti, Maria Pia
AU - Schumacher, Ton N.
AU - Debets, Reno
AU - Swartz, Melody A.
AU - Corti, Angelo
AU - Bellone, Matteo
AU - Mondino, Anna
N1 - Publisher Copyright:
©2016 American Association for Cancer Research.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Donor-derived allogeneic T cells evoke potent graft versus tumor (GVT) effects likely due to the simultaneous recognition of tumor-specific and host-restricted minor histocompatibility (H) antigens. Here we investigated whether such effects could be reproduced in autologous settings by TCR gene-engineered lymphocytes. We report that T cells redirected either to a broadly expressed Y-encoded minor H antigen or to a tumor-associated antigen, although poorly effective if individually transferred, when simultaneously administered enabled acute autochthonous tumor debulking and resulted in durable clinical remission. Y-redirected T cells proved hyporesponsive in peripheral lymphoid organs, whereas they retained effector function at the tumor site, where in synergy with tumor-redirected lymphocytes, they instructed TNFα expression, endothelial cell activation, and intratumoral T-cell infiltration. While neutralizing TNFα hindered GVT effects by the combined T-cell infusion, a single injection of picogram amounts of NGR-TNF, a tumor vessel-targeted TNFα derivative currently in phase III clinical trials, substituted for Y-redirected cells and enabled tumor debulking by tumor-redirected lymphocytes. Together, our results provide new mechanistic insights into allogeneic GVT, validate the importance of targeting the tumor and its associated stroma, and prove the potency of a novel combined approach suitable for immediate clinical implementation.
AB - Donor-derived allogeneic T cells evoke potent graft versus tumor (GVT) effects likely due to the simultaneous recognition of tumor-specific and host-restricted minor histocompatibility (H) antigens. Here we investigated whether such effects could be reproduced in autologous settings by TCR gene-engineered lymphocytes. We report that T cells redirected either to a broadly expressed Y-encoded minor H antigen or to a tumor-associated antigen, although poorly effective if individually transferred, when simultaneously administered enabled acute autochthonous tumor debulking and resulted in durable clinical remission. Y-redirected T cells proved hyporesponsive in peripheral lymphoid organs, whereas they retained effector function at the tumor site, where in synergy with tumor-redirected lymphocytes, they instructed TNFα expression, endothelial cell activation, and intratumoral T-cell infiltration. While neutralizing TNFα hindered GVT effects by the combined T-cell infusion, a single injection of picogram amounts of NGR-TNF, a tumor vessel-targeted TNFα derivative currently in phase III clinical trials, substituted for Y-redirected cells and enabled tumor debulking by tumor-redirected lymphocytes. Together, our results provide new mechanistic insights into allogeneic GVT, validate the importance of targeting the tumor and its associated stroma, and prove the potency of a novel combined approach suitable for immediate clinical implementation.
KW - EMB
UR - http://www.scopus.com/inward/record.url?scp=85012940152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012940152&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-16-0725
DO - 10.1158/0008-5472.CAN-16-0725
M3 - Article
C2 - 27872095
AN - SCOPUS:85012940152
SN - 0008-5472
VL - 77
SP - 658
EP - 671
JO - Cancer Research
JF - Cancer Research
IS - 3
ER -